Jyong Biotech Ltd. (MENS)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain
Jyong Biotech develops botanical drugs for urinary disorders. Their lead asset is clearly MCS‑2, which is currently restarting Phase 3 trials after a previous FDA setback. Their pipeline targets large unmet BPH, prostate cancer prevention, and IC markets. However, their botanical approach could be a potential “first‑in‑class” as a safer alternative. MENS recent IPO raised roughly $20 million and gave them a healthy cash runway. Though note that additional trials could accelerate cash burn.
Jyong Biotech Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LP Li Peng China Universal Asset Management Co. Ltd. | 12,389 | $48,936.55 | $21,185.19 | -$27,751.36 | -56.71% |
 Christopher C. Powers Farther Finance Advisors, LLC | 204 | $806 | $346.8 | -$459.2 | -56.97% |
| GFM GF Fund Management Co. Ltd. GF Fund Management Co. Ltd. | 1,677 | $6,292.65 | $2,683.2 | -$3,609.45 | -57.36% |
Jyong Biotech Ltd. (MENS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Jyong Biotech Ltd. ever had a stock split?
Jyong Biotech Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Fu-Feng Kuo CEO | NASDAQ (NMS) Exchange | G83116106 CUSIP |
| TW Country | 31 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Jyong Biotech Ltd. is a prominent biotech firm based in Taiwan that specializes in the research and development of novel therapeutic solutions derived from plants. The organization is particularly focused on targeting diseases of the urinary system, striving to improve the quality of life for patients suffering from these ailments. Through its subsidiaries, including Health Ever Bio-Tech and Genvace, Jyong Biotech Ltd. is advancing several drug candidates through various stages of clinical trials, showcasing its commitment to innovation in the biopharmaceutical field.
Products and Services
- MCS-2 (for BPH)
MCS-2 is a drug candidate currently in Phase III clinical trials aimed at treating Benign Prostatic Hyperplasia (BPH). This condition affects a significant proportion of older men, causing urinary problems. MCS-2 leverages plant-derived compounds to provide a natural and effective solution for alleviating the symptoms associated with BPH.
- PCP (for prostate cancer)
The PCP drug candidate is in Phase II clinical trials, designed specifically for the treatment of prostate cancer. This product integrates advanced biotechnology and plant-based research to create a targeted therapeutic option, focusing on improving patient outcomes and minimizing side effects.
- IC (in pre-clinical stages)
IC is a promising drug candidate currently in pre-clinical development, focused on addressing Interstitial Cystitis, a chronic condition leading to bladder pain and frequent urination. The pre-clinical research is aimed at demonstrating the efficacy and safety of this plant-derived treatment before it moves on to the clinical trial phase.
